000			03832nam a22003495i 4500
999			_c80559 _d80559 _x1
001			80559
003			ES-MaUEC
005			20230207040310.0
007			cr nn 008mamaa
008			140318s2014 gw | s |||| 0|eng d
020			_a9783642452574
024	7		_a10.1007/978-3-642-45257-4 _2doi
040			_aES-MaUEC _dES-MaUEC
050		4	_aRC514 _b.T743 2014
245	1	0	_aTreatment refractory Schizophrenia : _bA Clinical Conundrum _cedited by Peter F. Buckley, Fiona Gaughran.
260			_aBerlin, Heidelberg _bSpringer International Publishing _c2014
300			_a1 recurso en línea (VIII, 230 p.) _b7 ilustraciones, 6 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aDefinitions and scope of treatment-refractory schizophrenia -- Biology of schizophrenia: Is treatment-refractoriness synonymous with severity of illness -- Evolution of refractoriness -- Medical and psychiatric comorbidities:Â{u3BED}mplicating treatment expectations -- Overview of pharmacologic treatments and guidelines -- Clozapine:Â{u7BEC}ld standard treatment for refractory schizophrenia: Now or never -- Augmenting clozapine and other antipsychotic medications:Â{u0A21}rmacologic choices and differential outcomes -- Augmenting clozapine therapy:Â{u5B65}erging neuromodulatory strategies -- Cognitive remediation for refractory schizophrenia -- Psychological and familial therapies for refractory schizophrenia -- Vocational performance of patients with chronic schizophrenia -- Refractory schizophrenia and the criminal justice system:Â{u1826}failure of continuity of care and a real challenge -- Personalized medicine:Â{u1822}â€g̃ame changerâ€{u0A6E} the care of patients with treatment-refractory schizophrenia?
520			_aSchizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant populationÂ{u0B60}remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care. Â{u026E} this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused Â{u2BEF}k is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.
650		7	_2embne _9140524 _aEsquizofrenia
700	1		_aBuckley, Peter F _eeditor literario _942683
700	1		_aGaughran, Fiona _eeditor literario _988853 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-642-45257-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12883128 _b10-10-17 _c11-11-15
942			_2lcc _cLE
945			_aRC514 .T743 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11562948 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _ggw _h0